Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 16 February 2009, doi:10.1136/bmj.a3065
Cite this as: BMJ 2009;338:a3065
Treatments can increase HDL cholesterol, but do not independently reduce risk
| The first 150 words of the full text of this article appear below. |
History tends to repeat itself, in the medical sciences as in other domains. In the linked systematic review (doi:10.1136/bmj.b92), Briel and colleagues put high density lipoprotein (HDL) cholesterol into perspective as a marker of risk, and their findings evoke memories of other risk markers.1 Like HDL cholesterol, premature ventricular contractions are a validated risk marker for cardiovascular disease. Such contractions indicate an increased risk for adverse cardiovascular outcomes in the general population and in patients presenting with cardiovascular disease.2 3 Yet specific treatments that eliminate these contractions do not decrease the risk for adverse outcomes and can even increase risk.4 Thus, modifying the known marker of increased risk does not necessarily modify the risk itself.
Briel and colleagues demonstrate this phenomenon for HDL cholesterol in a meta-regression study of 108 clinical trials that assessed more than 300 000 patients and several lipid modifying treatments.1 They found that although some
William A Ghali, professor1, Nicolas Rodondi, senior lecturer2
1 Departments of Medicine and Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, T2N 4N1, 2 Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, CH1011, Switzerland
wghali@ucalgary.ca
Read all Rapid Responses